What is the role of liquid biopsy in patients with metastatic castration resistant prostate cancer to asses BRCA1/2 or other mutations and consider PARP inhibitors?

There are no FDA cleared tests that have been shown to accurately predict response or benefit from PARP inhibitors in men with prostate cancer. The risk of both false positives and false negatives remains high with these assays due and no studies in prostate cancer have shown concordance with a high...

Liquid biopsy (plasma or cfDNA testing) has an important role in identifying patients who may be eligible for PARP inhibitors or pembrolizumab for MSI-high prostate cancer. It also has an important role in screening for trials of other targeted agents (e.g. ATR inhibitors, AKT inhibitors). Both stud...